Idiopathic pulmonary fibrosis
Top Cited Papers
- 20 October 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Disease Primers
- Vol. 3 (1), 17074
- https://doi.org/10.1038/nrdp.2017.74
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It is associated with increasing cough and dyspnoea and impaired quality of life. IPF affects ∼3 million people worldwide, with incidence increasing dramatically with age. The diagnostic approach includes the exclusion of other interstitial lung diseases or overlapping conditions and depends on the identification of the UIP pattern, usually with high-resolution CT; lung biopsy might be required in some patients. The UIP pattern is predominantly bilateral, peripheral and with a basal distribution of reticular changes associated with traction bronchiectasis and clusters of subpleural cystic airspaces. The biological processes underlying IPF are thought to reflect an aberrant reparative response to repetitive alveolar epithelial injury in a genetically susceptible ageing individual, although many questions remain on how to define susceptibility. Substantial progress has been made in the understanding of the clinical management of IPF, with the availability of two pharmacotherapeutic agents, pirfenidone and nintedanib, that decrease physiological progression and likely improve progression-free survival. Current efforts are directed at identifying IPF early, potentially relying on combinations of biomarkers that include circulating factors, demographics and imaging data.Keywords
This publication has 244 references indexed in Scilit:
- Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblastsCell Death & Disease, 2013
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Cytokine-Like Factor 1 Gene Expression Is Enriched in Idiopathic Pulmonary Fibrosis and Drives the Accumulation of CD4+ T Cells in Murine LungsThe American Journal of Pathology, 2012
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- A CommonMUC5BPromoter Polymorphism and Pulmonary FibrosisNew England Journal of Medicine, 2011
- Feedback amplification of fibrosis through matrix stiffening and COX-2 suppressionThe Journal of cell biology, 2010
- A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2010
- Identification of Early Interstitial Lung Disease in Smokers from the COPDGene StudyAcademic Radiology, 2009
- Short telomeres are a risk factor for idiopathic pulmonary fibrosisProceedings of the National Academy of Sciences, 2008
- Adult-onset pulmonary fibrosis caused by mutations in telomeraseProceedings of the National Academy of Sciences, 2007